Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone + trastuzumab versus docetaxel + trastuzumab in HER2-positive advanced or metastatic breast cancer
2007-000721-21Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Ixabepilone + trastuzumab with Docetaxel + trastuzumab (2 arms). Primary endpoints: Objective response, Response rate for ixabepilone plus trastuzumab and 1 more. Started Jun 2007; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-000721-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000721-21.